Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Study Identifier:
TORL123-002
CT.gov Identifier:
NCT06690775
EudraCT Identifier:
202452000000
EU Trial (CTIS) Number:
2024-517190-24-00
Study Contact Information:
N/A
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

The study is designed to support accelerated registration in CLDN6+ PROC

To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced platinum-resistant ovarian cancer (PROC) expressing CLDN6

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Ovarian
  • Primary Peritoneal
  • Fallopian Tube
  • Endometrial
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    II
    Sex
    Female
    Age
    18+ years
    Study Drug
  • Drug: Experimental: Cohort 1
    • Read More
  • Drug: Intervention:
  • Drug: Drug: Pegfilgrastim (drug)
  • Drug: Experimental: Cohort 2
  • Drug: Experimental: Cohort 3
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Recruiting

    Requirements information
    Inclusion criteria
    • Participants are eligible to be included in the study only if all the following criteria apply:
    • 1. Females ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the informed consent.
    • 2. Participants must sign the informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    • 3. Disease Type:
    • * Histologically or cytologically confirmed diagnosis of advanced (unresectable) or metastatic high grade serous ovarian, primary peritoneal (i.e. of primary origin), or fallopian tube cancer. High-grade endometrioid ovarian cancer is permitted for enrollment.
    • * Participant's tumor must be positive for CLDN6 expression as defined by the CLDN6 reference laboratory assay. Tumor tissue will be required for submission for CLDN6 testing prior to Cycle 1 Day 1.
    • * Participants must have platinum-resistant disease, defined as the following:
    • * If participants received only 1 line of platinum-based therapy, they must have completed 4 or more cycles of platinum-containing therapy, must have achieved a CR or PR, and progressed \>3 months but ≤6 months after the last dose of platinum.
    • * Participants who have received more than 1 line of platinum- based therapy must have progressed on or within 6 months after the last dose of platinum.
    • * NOTE: This should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression (per RECIST v1.1).
    • * Participants who are platinum-refractory during front-line treatment are excluded.
    • * Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single- agent therapy is appropriate as the next line of treatment. Study rules for evaluation of number of prior systemic lines of therapy:
    • * Adjuvant ± neoadjuvant is considered one line of therapy
    • * Maintenance therapy (eg, bevacizumab or PARP inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently)
    • * Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)
    • * Hormonal therapy will not be counted as a separate line of therapy
    • 4. Measurable disease, per RECIST v1.1
    • 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
    • 6. Adequate organ function, based on the following laboratory values:
    • * ANC: ≥1,500/mcL
    • * Platelets: ≥100,000/mcL without transfusion within 4 weeks of first dose
    • * Hemoglobin: 9 g/dL with transfusion or EPO support up to 14 days before eligibility assessment
    • * Measured or calculated creatinine clearance with a validated formula\*: ≥30 mL/min
    • * Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease or liver metastases who have serum bilirubin level ≤3×ULN may be enrolled
    • * AST (SGOT) and ALT (SGPT): ≤3 X ULN (participants with active liver metastases who have ALT/AST ≤5 X ULN may be enrolled)
    • * Albumin: ≥2.5 g/dL
    • * ECG: 12-Lead ECG with normal tracing or non-clinically significant changes that do not require medical intervention and QTcF interval
    • * 470 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality.
    • 7. Participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug treatment. The serum pregnancy test must be negative for the participant to be eligible.
    • 8. Participants must agree to use a highly effective birth control method from the time of the first study drug treatment through 7 months after the last study drug treatment, or be of nonchildbearing potential.
    • 9. Participants must agree not to donate eggs from the first study drug treatment through 7 months after the last study drug treatment.
    • 10. Participants must agree to not breastfeed from the first dose of study treatment through 90 days after the last dose of study treatment.
    • Females aged 18 years or older with confirmed diagnosis of advanced (unresectable) or metastatic high grade serious ovarian, primary peritoneal (ie, of primary origin), or fallopian tube cancer that resistant to platinum-containing therapy.
    • Participant’s tumor must show claudin 6 expression, as defined by the claudin 6 reference laboratory assay.
    • Have measurable tumor at baseline
    • Key inclusion criteria are recurrent PROC, up to 3 prior regimens, CLDN6+ disease via central IHC testing.
    Exclusion criteria
    • Participants are excluded from the study if any of the following criteria apply:
    • 1. Has not recovered [recovery is defined as National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
    • 2. Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers.
    • 3. Participants with primary platinum-refractory ovarian, primary peritoneal (i.e. of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy.
    • 4. Received prior chemotherapeutic, investigational, radiotherapy, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23. There is no waiting period required for stereotactic radiosurgery.
    • 5. Prior treatment with a CLDN6-targeting agent or an MMAE-containing ADC.
    • 6. Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.
    • 7. Grade 2 or greater peripheral neuropathy.
    • 8. History of non-infectious pneumonitis/ILD within 6 months of first dose of study drug.
    • 9. Participants must not be considered a high medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
    • 10. History of significant cardiac disease:
    • 1. Congestive heart failure >New York Heart Association class 2 within last year
    • 2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
    • 3. Myocardial infarction less than 6 months before start of study drug
    • 4. Anti-arrhythmic therapy (beta blockers are permitted)
    • 5. Any unstable ischemic disease or untreated arrhythmia
    • 11. Known history of myelodysplastic syndrome or acute myeloid leukemia.
    • 12. History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. Participants with malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ of the breast are not excluded.
    • 13. Uncontrolled infection; active, clinically serious infections (CTCAE Grade >2).
    • 14. Participants with seizure disorder requiring medication.
    • 15. Known hypersensitivity or intolerance to any of the study drugs, study drug classes, or excipients in the formulation.
    • 16. History of having an allogeneic bone marrow or organ transplant.
    • 17. Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator.
    • 18. Participants who are taking any drugs that are strong inducers and/or strong inhibitors of CYP3A4 enzymes.
    • 19. Participants who are taking any drugs that are inhibitors of P-glycoprotein.
    • Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers
    • Participants with primary platinum-refractory ovarian, primary peritoneal (ie, of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy
    • Still experiencing significant side effects from previous cancer treatments
    • Recently received other cancer treatments (within 14 days for most drugs, or 28 days for biologics) before starting this new drug.
    • Has received treatment with a CLDN6-targeting agent or an monomethyl auristatin E (MMAE)-containing antibody drug conjugate
    • Key exclusion criteria are primary platinum refractory disease and prior treatment with a CLDN6-targeting ADC or MMAE-containing ADC.

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START Dublin
    Dublin, Ireland, D07 R2WY
    Investigator
    Austin Duffy
    Status
    Recruiting
    Condition(s) Treated at Site
    Ovarian
    Primary Peritoneal
    Fallopian Tube
    Endometrial